Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 14

Effect of tiotropium/olodaterol on sedentary and active time in patients with COPD: post hoc analysis of the VESUTO® study

Authors Minakata Y, Motegi T, Ueki J, Gon Y, Nakamura S, Anzai T, Hirata K, Ichinose M

Received 12 March 2019

Accepted for publication 10 July 2019

Published 7 August 2019 Volume 2019:14 Pages 1789—1801

DOI https://doi.org/10.2147/COPD.S208081

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 2

Editor who approved publication: Dr Richard Russell


Yoshiaki Minakata,1 Takashi Motegi,2 Jun Ueki,3 Yasuhiro Gon,4 Shuhei Nakamura,5 Tatsuhiko Anzai,6 Kazuto Hirata,7 Masakazu Ichinose8

1Department of Respiratory Medicine, National Hospital Organization Wakayama Hospital, Wakayama, Japan; 2Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan; 3Clinical Research Unit of Respiratory Pathophysiology, Juntendo University Graduate School of Health Care and Nursing, Chiba, Japan; 4Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan; 5Medical Division, Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan; 6Clinical Information Division Data Science Center, Statistics Analysis Department 1, EPS Corporation, Tokyo, Japan; 7Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Osaka, Japan; 8Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan

Background: Patients with COPD are less physically active. This post hoc analysis of a randomized, double-blind, active-controlled, crossover trial assessed the efficacy of once-daily tiotropium/olodaterol combination therapy versus tiotropium monotherapy in Japanese patients with COPD.
Patients and methods: Patients were provided with a three-axis accelerometer to measure sedentary and active behavior defined as 1.0–1.5 metabolic equivalents (METs), ≥2.0 METs, and ≥3.0 METs, respectively. Of the 182 patients enrolled, 131 satisfied the conditions for the present analysis and were randomized to tiotropium monotherapy (n=62) or tiotropium/olodaterol combination therapy (n=69).
Results: Tiotropium/olodaterol combination therapy significantly reduced the duration of 1.0–1.5 MET activity by 8.64 mins (p=0.040) and significantly increased the duration of ≥2.0 MET and ≥3.0 MET activity by 6.51 mins (p=0.017) and 2.60 mins (p=0.008), respectively, compared with tiotropium alone. Subgroup analyses showed that better lung function, milder dyspnea, and higher levels of physical activity at baseline were associated with reduced sedentary time and increased duration of physical activity.
Conclusion: Tiotropium/olodaterol combination therapy significantly reduced sedentary time and improved physical activity compared with tiotropium monotherapy. This trial was registered in ClinicalTrials.gov (NCT02629965).

Keywords: COPD, Japanese, physical activity, sedentary behavior

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]